On April 16, 2018, the Food and Drug Administration granted approvals to nivolumab and ipilimumab (Opdivo® and Yervoy®, Bristol-Myers Squibb Co.) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
Members of ASCO's Leadership Development Program held a Hill Day to advocate for federal research funding, oral parity, step therapy, and other cancer policy priorities.
ASCO submitted a budget request to a House Committee on Appropriations subcommittee, asking for $3.32 billion in funding for the Food and Drug Administration (FDA) and support for the Administration’s request of $20 million for FDA’s Oncology Center of Excellence (OCE) in Fiscal Year (FY) 2019.
Clinicians can now use the updated Participation Lookup Tool from the Centers for Medicare & Medicaid Services (CMS) to check their 2018 eligibility for the Merit-Based Incentive Payment System (MIPS) under the Quality Payment Program (QPP). Within the online tool, clinicians can enter their National Provider Identifier (NPI) to find out whether or not they need to participate in MIPS during the 2018 performance year.
Nominated by ASCO, as part of its ongoing commitment to ensure the success of its members in Quality Payment Program implementation and participation, eight ASCO volunteers have been chosen to serve on the Centers for Medicare and Medicaid Services (CMS) Oncology Clinical Subcommittee that will provide input on the development of episode-based cost measures for potential use in the Quality Payment Program.
On April 10, 2018, the Food and Drug Administration approved everolimus tablets for oral suspension (Afinitor Disperz®, Novartis Pharmaceuticals Corp.) for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC: TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma
On April 6, 2018, the Food and Drug Administration approved rucaparib (Rubraca®, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Applications for the Alexandria, Va. session of ASCO’s Quality Training Program, being held at ASCO headquarters, are being accepted now through June 4.
President Trump recently announced that his Administration is developing a “three-pronged plan” to help combat the opioid epidemic in the United States. The announcement comes after the Food and Drug Administration’s (FDA) Opioid Policy Steering Committee released a notice earlier this year requesting comments on several questions related to opioid prescribing, provider education, and prescription drug monitoring programs. ASCO recently submitted extensive comments to the steering committee addressing these questions and reiterating the importance of special consideration of the cancer patient population.
ASCO continues to partner with state societies on cancer policy priorities under consideration in states across the country.
On April 2, ASCO released a video that features several physicians who work at various practice types that have achieved Quality Oncology Practice Initiative (QOPI®) Certification discussing what this certification means to them, their staff, and their patients.
Eligible clinicians participating in the Quality Payment Program (QPP) will now be able to submit 2017 Merit-based Incentive Payment System (MIPS) performance data until Tuesday, April 3, 2018 at 8:00 PM ET. Clinicians can submit their 2017 performance data using the QPP website.
Linda D. Bosserman, MD, FACP, FASCO, has been named Editor-in-Chief of the Journal of Oncology Practice (JOP), a publication of ASCO. Dr. Bosserman is a recognized leader in cancer care delivery with a deep understanding of the issues impacting all types of oncology practices.
On March 29, 2018, the Food and Drug Administration granted accelerated approval to blinatumomab (Blincyto®, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
The American Society of Clinical Oncology (ASCO) applauds Congress for its bipartisan support of the omnibus spending bill that significantly boosts our nation's investment in biomedical research. By providing a $3 billion funding increase for the National Institutes of Health (NIH) for fiscal year (FY) 2018—the biggest NIH funding increase in 15 years—Congress has taken bold action to regain much-needed momentum in cancer research following a decade of stagnant funding for the NIH